A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer.
Schelman WR; Liu G; Wilding G; Morris T; Phung D; Dreicer R; Investigational New Drugs, 2011, vol. 29, issue 1, p 118, ISSN 15730646. ISBN 15730646.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef